The E3 ubiquitin ligase HACE1 is a potent tumor suppressor that controls cell proliferation and ubiquitylates the small GTPase Rac1 to target it to proteasomal degradation. Whether and how the activity of HACE1 is regulated by the N-terminal ankyrin (ANK) and the middle (MID) domains is ill defined. Here, we identified in the version 64 of the Catalogue of Somatic Mutations in Cancer (COSMIC) 13 missense mutations of hace1 located outside the HECT domain, and found that all lead to defective control of cell proliferation. In addition, several mutations located in the ankyrin domain displayed a dramatic reduction in Rac1 ubiquitylation associated with a decrease of colony formation in soft agar. 3D structure modelling of the 7 ankyrin-repeats coupled to functional analysis identified a surface epitope centered on one of the mutated residue, Gly-175, which is critical for controlling Rac1 binding and ubiquitylation. We also identified a role for the MID domain in conferring the specificity of association of HACE1 to the active form of Rac1. Our study of the functional interplay between HACE1 and Rac1 in cancer thus sheds a new light on the molecular mechanism of Rac1 ubiquitylation by HACE1 and the impact of its cancer-associated mutations in cell proliferation.
30 August 2024 in Journal of Experimental Medicine
A growing number of patients presenting severe combined immunodeficiencies attributed to monoallelic RAC2 variants have been identified. The expression of the RHO GTPase RAC2 is restricted to the hematopoietic lineage. RAC2 variants have been described to cause immunodeficiencies associated with high frequency of infection, leukopenia, and autoinflammatory features. Here, we show that specific RAC2 activating mutations induce the NLRP3 inflammasome activation leading to the secretion of IL-1β and IL-18 from macrophages. This activation depends on the activation state of the RAC2 variant and is mediated by the downstream kinase PAK1. Inhibiting the RAC2–PAK1–NLRP3 inflammasome pathway might be considered as a potential treatment for these patients.
Adaptive immune memory generated by bacterial toxin vaccination is well established, but whether bacterial toxins can also induce innate immune memory, or trained immunity (TI), remains unclear. Here, we show that bacterial toxins elicit TI through NLRP3 inflammasome activation both in vitro and in vivo in mice, and that this response is conserved in primary human macrophages. Stimulation with the CNF1 toxin induced an epigenetic remodeling, defining a TI-associated transcriptional signature. A targeted RNAi screen identified Bcl2a1 as a required mediator of TI, and epistasis analyses demonstrated that IL-1 signaling is essential for TI induction in macrophages. In our mouse sepsis model, toxin-induced TI enhanced host resistance and improved survival. These findings establish toxin-driven inflammasome activation as trigger of transient TI and demonstrate that this response enhance resistance during experimental bacterial sepsis.